生物制药公司Annexon, Inc. (ANNX) 已正式向欧洲药品管理局(EMA)提交了其候选药物Tanruprubart的上市授权申请(MAA),该药物拟用于治疗格林-巴利综合征(GBS)。此次提交标志着公司在推进该创新疗法于欧洲市场获批的重要一步。
生物制药公司Annexon, Inc. (ANNX) 已正式向欧洲药品管理局(EMA)提交了其候选药物Tanruprubart的上市授权申请(MAA),该药物拟用于治疗格林-巴利综合征(GBS)。此次提交标志着公司在推进该创新疗法于欧洲市场获批的重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.